Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Underwood

Showing results (31-40 of 53) with videos related to

Pageof 6
Sort By:
Viruses|June 28, 2023
Assessing the Virologic Impact of Archived Resistance in the Dolutegravir/Lamivudine 2-Drug Regimen HIV-1 Switch Study TANGO through Week 144Ruolan Wang, Jonathan Wright, Parminder Saggu, et al.
Open Forum Infectious Diseases|January 12, 2024
Very-Low-Level Viremia, Inflammatory Biomarkers, and Associated Baseline Variables: Three-Year Results of the Randomized TANGO StudyRuolan Wang, Mark Underwood, Josep M Llibre, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 2, 2022
Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, Noninferiority SALSA Randomized TrialJosep M Llibre, Carlos Brites, Chien-Yu Cheng, et al.
The Lancet. Infectious Diseases|February 9, 2019
Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trialMichael Aboud, Richard Kaplan, Johannes Lombaard, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 18, 2020
Brief Report: Durable Suppression and Low Rate of Virologic Failure 3 Years After Switch to Dolutegravir + Rilpivirine 2-Drug Regimen: 148-Week Results From the SWORD-1 and SWORD-2 Randomized Clinical TrialsJean van Wyk, Chloe Orkin, Rafael Rubio, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 12, 2026
Proof-of-Concept Phase 2a Trial of VH4524184 (VH-184), an Emerging Third-Generation Integrase Strand Transfer Inhibitor With an Enhanced Resistance ProfileLuise Rogg, Sebastian A Nuñez, María Verónica Mingrone, et al.
Antiviral Research|July 16, 2008
Selection of diverse and clinically relevant integrase inhibitor-resistant human immunodeficiency virus type 1 mutantsMasanori Kobayashi, Koichiro Nakahara, Takahiro Seki, et al.
The Lancet. HIV|July 17, 2019
Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studiesMichael Aboud, Chloe Orkin, Daniel Podzamczer, et al.
Optics Express|January 26, 2012
Review of fluorescent standards for calibration of in situ fluorometers: recommendations applied in coastal and ocean observing programsAlan Earp, Christine E Hanson, Peter J Ralph, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 25, 2020
Brief Report: Virologic Response by Baseline Viral Load With Dolutegravir Plus Lamivudine vs Dolutegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled AnalysisJoseph Eron, Chien-Ching Hung, Jean-Guy Baril, et al.
Pageof 6

Showing results (31-40 of 53) with videos related to

Sort By:
Pageof 6
Viruses|June 28, 2023
Assessing the Virologic Impact of Archived Resistance in the Dolutegravir/Lamivudine 2-Drug Regimen HIV-1 Switch Study TANGO through Week 144Ruolan Wang, Jonathan Wright, Parminder Saggu, et al.
Open Forum Infectious Diseases|January 12, 2024
Very-Low-Level Viremia, Inflammatory Biomarkers, and Associated Baseline Variables: Three-Year Results of the Randomized TANGO StudyRuolan Wang, Mark Underwood, Josep M Llibre, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 2, 2022
Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, Noninferiority SALSA Randomized TrialJosep M Llibre, Carlos Brites, Chien-Yu Cheng, et al.
The Lancet. Infectious Diseases|February 9, 2019
Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trialMichael Aboud, Richard Kaplan, Johannes Lombaard, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 18, 2020
Brief Report: Durable Suppression and Low Rate of Virologic Failure 3 Years After Switch to Dolutegravir + Rilpivirine 2-Drug Regimen: 148-Week Results From the SWORD-1 and SWORD-2 Randomized Clinical TrialsJean van Wyk, Chloe Orkin, Rafael Rubio, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 12, 2026
Proof-of-Concept Phase 2a Trial of VH4524184 (VH-184), an Emerging Third-Generation Integrase Strand Transfer Inhibitor With an Enhanced Resistance ProfileLuise Rogg, Sebastian A Nuñez, María Verónica Mingrone, et al.
Antiviral Research|July 16, 2008
Selection of diverse and clinically relevant integrase inhibitor-resistant human immunodeficiency virus type 1 mutantsMasanori Kobayashi, Koichiro Nakahara, Takahiro Seki, et al.
The Lancet. HIV|July 17, 2019
Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studiesMichael Aboud, Chloe Orkin, Daniel Podzamczer, et al.
Optics Express|January 26, 2012
Review of fluorescent standards for calibration of in situ fluorometers: recommendations applied in coastal and ocean observing programsAlan Earp, Christine E Hanson, Peter J Ralph, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 25, 2020
Brief Report: Virologic Response by Baseline Viral Load With Dolutegravir Plus Lamivudine vs Dolutegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled AnalysisJoseph Eron, Chien-Ching Hung, Jean-Guy Baril, et al.
Pageof 6